Page last updated: 2024-12-08
4-(2-Amino-1,3-thiazol-4-yl)phenol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 346926 |
| CHEMBL ID | 483790 |
| CHEBI ID | 194604 |
| SCHEMBL ID | 5321407 |
Synonyms (44)
| Synonym |
|---|
| STK723345 |
| BB 0258249 |
| SDCCGMLS-0065861.P001 |
| OPREA1_415030 |
| AE-641/01182060 |
| 4-(2-amino-1,3-thiazol-4-yl)phenol |
| nsc405294 |
| 57634-55-6 |
| nsc-405294 |
| 4-(2-amino-thiazol-4-yl)-phenol |
| 92G , |
| AKOS000303315 |
| DB07292 |
| CHEMBL483790 , |
| CHEBI:194604 |
| 4-(2-aminothiazol-4-yl)phenol |
| bdbm50293592 |
| A831534 |
| EN300-81724 |
| 2-amino-4-(4-hydroxyphenyl)thiazole |
| 2-amino-4-(4-hydroxyphenyl)-thiazole |
| FT-0677313 |
| F0370-0333 |
| 4-(2-amino-4-thiazolyl)phenol |
| SCHEMBL5321407 |
| 3FU3 |
| SY012597 |
| mfcd01624171 |
| FS-1402 |
| phenol, 4-(2-amino-4-thiazolyl)- |
| 4-(2-amino-1,3-thiazol-4-yl)phenol # |
| p-(2-amino-4-thiazolyl)phenol |
| HMS3604B06 |
| sr-01000492488 |
| SR-01000492488-1 |
| CS-0096820 |
| DTXSID30323956 |
| 4-(2-amino-1,3-thiazol-4-yl)phenol, aldrichcpr |
| MLP0GI2196 , |
| unii-mlp0gi2196 |
| Q27096518 |
| AMY319 |
| PD005376 |
| Z227972914 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (21)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Chain A, Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,443.0000 | 212.0000 | 1,235.3333 | 2,000.0000 | AID977608 |
| Fructose-1,6-bisphosphatase 1 | Sus scrofa (pig) | IC50 (µMol) | 1.1000 | 1.1000 | 1.3250 | 1.6000 | AID419859 |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 1,221.5000 | 0.0005 | 1.2854 | 7.6500 | AID420374; AID420375 |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 57.0000 | 0.0070 | 1.1169 | 3.0100 | AID1582589 |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | IC50 (µMol) | 60.0000 | 0.0070 | 0.9594 | 6.2700 | AID1582590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (17)
Molecular Functions (16)
Ceullar Components (10)
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1196570 | Binding affinity to protein kinase (unknown origin) at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID397259 | Inhibition of Trypanosoma brucei pteridine reductase 1 at 100 uM | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. |
| AID1196566 | Binding affinity to oxidoreductase 1 (unknown origin) at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID1582589 | Inhibition of N-terminal GST-tagged MNK1 (unknown origin) (37 to 341 residues) expressed in Escherichia coli BL21 (DE3) cells using 5-FAM-TATKSGSTTKNRFVV-NH2 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition after 60 | 2020 | Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2 | Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2. |
| AID1196567 | Binding affinity to Plasmodium falciparum AMA1 at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID1196569 | Binding affinity to carbonic anhydrase 2 (unknown origin) at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID420376 | Inhibition of ionomycin-stimulated LTB4 production in human whole blood treated 15 mins prior to ionomycin challenge measured after 30 mins of stimulation by enzyme-linked immunosorbent assay | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. |
| AID1196568 | Binding affinity to SPSB2 (unknown origin) at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID1196565 | Binding affinity to oxidoreductase 2 (unknown origin) at 200 uM by surface plasmon resonance method | 2015 | Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. |
| AID419859 | Inhibition of pig FBPase expressed in Escherichia coli EK1601 by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. |
| AID420374 | Inhibition of peptidase activity of human recombinant LTA4H expressed in Escherichia coli BL21-AI/pRARE | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. |
| AID420373 | Solubility in methanol | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. |
| AID420375 | Inhibition of hydrolase activity of human recombinant LTA4H expressed in Escherichia coli BL21-AI/pRARE assessed as LTB4 formation by tandem quadrupole mass spectrometry | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. |
| AID1582590 | Inhibition of N-terminal GST-tagged MNK2 (unknown origin) (72 to 385 residues) expressed in Escherichia coli BL21 (DE3) cells using 5-FAM-TATKSGSTTKNRFVV-NH2 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition after 60 | 2020 | Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2 | Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||